US pharma major Eli Lilly (NYSE: LLY) and not-for-profit Sanford-Burnham Medical Research Institute have signed an immunological collaboration to investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren's syndrome, inflammatory bowel disease and other autoimmune disorders.
Collaboration co-chairman Thomas Bumol, senior vice president, biotechnology and immunology research at Lilly, said: “Immunology is an important research area of focus for Lilly, and through this exciting collaboration with Sanford-Burnham, our scientists can discover and develop new medicines together in a seamless way that takes advantage of each group in a family of key targets.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze